ProCE Banner Activity

PAOLA-1 Phase III Trial: Final Overall Survival Results of Maintenance Olaparib + Bevacizumab in Patients With Newly Diagnosed Advanced Ovarian Cancer

Slideset Download
Conference Coverage
Final OS data for the PAOLA-1 trial support the addition of olaparib to bevacizumab for patients with HRD-positive ovarian cancer receiving treatment in the frontline setting.

Released: September 27, 2022

Expiration: September 26, 2023

No longer available for credit.


Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by educational grants from


Bristol Myers Squibb

Exelixis, Inc.

Gilead Sciences, Inc.

Merck Sharp & Dohme Corp.